Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alvogen
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: South Korea
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07678827 |
AK-D101_BS | P3 |
Not yet recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-09-01 |
41% |
2026-07-02 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|